ADMA Biologics ADMA Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts
Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's accounts receivable allowance for contractual credits and doubtful accounts.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's accounts receivable allowance for contractual credits and doubtful accounts?
- ADMA Biologics (ADMA) reported accounts receivable allowance for contractual credits and doubtful accounts of $200K in Q1 2026.
- How has ADMA Biologics's accounts receivable allowance for contractual credits and doubtful accounts changed year-over-year?
- ADMA Biologics's accounts receivable allowance for contractual credits and doubtful accounts decreased by 93.3% year-over-year, from $3M to $200K.
- What is the long-term trend for ADMA Biologics's accounts receivable allowance for contractual credits and doubtful accounts?
- Over 5 years (2020 to 2025), ADMA Biologics's accounts receivable allowance for contractual credits and doubtful accounts has grown at a 24.6% compound annual growth rate (CAGR), from $100K to $300K.
- What does accounts receivable allowance for contractual credits and doubtful accounts mean?
- This is a contra-asset account representing the estimated portion of accounts receivable that may not be collected due to contractual adjustments, rebates, or credit losses. It provides insight into the quality of the company's revenue and the effectiveness of its credit management policies. A rising allowance may indicate increasing collection risks or aggressive revenue recognition practices.